Literature DB >> 12972956

The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia.

Irina Costea1, Albert Moghrabi, Maja Krajinovic.   

Abstract

The 870A>G polymorphism in the cyclin D1 (CCND1) gene modulates mRNA splicing, leading to altered protein that may affect the regulation of the G1/S cell-cycle checkpoint. This polymorphism has been reported to influence susceptibility to and progression of several malignancies. Furthermore, the change of retinoblastoma protein regulation mediated by CCND1 may play a role in the development of methotrexate (MTX) resistance via an associated higher activity of enzymes that are inhibited by MTX. This study shows that children with acute lymphoblastic leukaemia (ALL) who are homozygous for the CCND1 A variant have a lower probability of event-free survival (P = 0.006) compared to carriers of the G variant. A significant result is retained in the presence of other prognostic factors. This impact is even more apparent in individuals who are also homozygous for thymidylate synthase (TS) triple repeat (P < 0.00005), which has previously been shown to influence the outcome of childhood ALL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972956     DOI: 10.1097/00008571-200309000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  10 in total

1.  Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.

Authors:  Xuwei Hou; Sili Wang; Yuling Zhou; Ziliang Xu; Yao Zou; Xiaofan Zhu; Mingzhe Han; Tianxiang Pang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

2.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

Review 3.  Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.

Authors:  Yang Chen; Zuojun Shen
Journal:  Tumour Biol       Date:  2015-05-30

4.  Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.

Authors:  Biljana Jekic; Ljiljana Lukovic; Vera Bunjevacki; Vera Milic; Ivana Novakovic; Tatjana Damnjanovic; Jelena Milasin; Branka Popovic; Nela Maksimovic; Nemanja Damjanov; Goran Radunovic; Ljiljana Kovacevic; Maja Krajinovic
Journal:  Eur J Clin Pharmacol       Date:  2012-07-05       Impact factor: 2.953

Review 5.  Thymidylate synthase pharmacogenetics.

Authors:  Sharon Marsh
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

6.  Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?

Authors:  Phuong Thu Vu Hoang; Jérôme Ambroise; Anne-France Dekairelle; Jean-François Durant; Valentina Butoescu; Vu Luan Dang Chi; Nghia Huynh; Tan Binh Nguyen; Annie Robert; Christiane Vermylen; Jean-Luc Gala
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

7.  CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.

Authors:  Yao Xue; Liucheng Rong; Na Tong; Meilin Wang; Zhengdong Zhang; Yongjun Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 8.  Pharmacogenetics in acute lymphoblastic leukemia.

Authors:  Meyling H Cheok; Nicolas Pottier; Leo Kager; William E Evans
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 9.  Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?

Authors:  Sunitha Kodidela; Pradhan Suresh Chandra; Biswajit Dubashi
Journal:  Eur J Clin Pharmacol       Date:  2013-12-27       Impact factor: 2.953

Review 10.  Targeting cell cycle regulators in hematologic malignancies.

Authors:  Eiman Aleem; Robert J Arceci
Journal:  Front Cell Dev Biol       Date:  2015-04-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.